Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
New insights into COVID-19 infectiousness
Fri August 19th - British researchers have unveiled the first real-world study to estimate how long people are infectious with mild COVID-19. More
Gene variant that protects against heart disease
Fri August 19th - A gene variant has been identified that helps to protect against heart diseases. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

New treatment hope after T cell activation discovery

Friday May 27th 2022

Links between more than 100 genes and immune-system related diseases have been identified for the first time, offering hope of new therapies, British scientists say.

A team from Open Targets, the Wellcome Sanger Institute, Cambridge, UK, and GSK say their first-of-its-kind experiment provides new insights into the sequence and timing of gene activity during the activation of T cells.

The three-year research study shows that numerous disease-linked variants are active during different stages of T cell activation.

Researchers said the findings would help in development of treatments for diseases such as rheumatoid arthritis, type 1 diabetes and Crohn’s disease.

They profiled more than 650,000 individual cells using single-cell RNA sequencing technology to map the timing of gene activity for each cell subtype in the T cell activation process, identifying genes regulated by variations in DNA that were switched on or off in each cell.

More than 6,400 genes involved in the activation process were identified and by comparing their data with known genetic variants for 13 immune diseases, found 127 genes associated with those diseases.

Some of these manifested at specific time points and have not been previously studied, they write in today’s *Nature Genetics*.

First author Dr Blagoje Soskic, of the Wellcome Sanger Institute, said: “By profiling multiple time points during T cell activation, our study emphasises that genetic regulation can be specific for a particular cell state.

“Crucially, we were able to associate DNA variants with changes in the activity of specific genes, in particular cell types, at various times in the activation process. This unprecedented granularity is key to better understanding T cell activation, providing more in-depth data with which to pursue new treatments for immune disorders.”

The research team say their work is the first step to a deeper understanding of immune processes and how they go awry in diseases.

Follow-up studies, in which each gene will be altered individually to observe how this affects the T cell activation, are now needed to provide insights into how immune processes can be affected by variations in DNA, and how immune-mediated diseases develop.

John Lepore, senior vice-president and head of research at GSK, said: “This study is already informing our early discovery portfolio by providing a novel, rich data set we are actively using to select genetically-informed drug targets for further validation experiments.”

The study focused on genes involved in 13 immune diseases, but the approach and data generated can be applied to identifying genes involved in other disorders and the team hope it will shed light on how diseases are related or underpinned by similar biological processes and highlight genetic risk factors.

Dr Gosia Trynka, the senior author of the study from the Wellcome Sanger Institute and Experimental Science Director of Open Targets, said: “Our data will provide crucial insight into key immune system mechanisms, helping us to understand which genes are affected, what might be causing disease, and what factors might be putting patients at risk.

“In particular, the ability to link genetic variants strongly tied to immune diseases with changes in the activity of genes during this activation is a crucial first step to developing new treatments.”

Soskic B, Cano-Gamez E et al. Immune disease risk variants regulate gene expression dynamics during CD4+ T cell activation. *Nature Genetics* 26 May 2022


Tags: Diabetes | Genetics | Rheumatology | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)